Journal article
Exacerbations of Severe Asthma While on Anti-IL-5 Biologics.
Abstract
Anti-interleukin 5 (IL-5) and anti-IL-5 receptor α monoclonal antibodies markedly decrease airway and peripheral blood eosinophil numbers and are thus highly effective in reducing asthma exacerbations. Nonetheless, these biologics do not completely resolve exacerbations. There is very little information on the cellular nature of exacerbations during treatment with biologics. Using illustrative clinical case scenarios, we highlight the …
Authors
Bhalla A; Zhao N; Rivas DD; Ho T; Perez de Llano L; Mukherjee M; Nair P
Journal
Journal of Investigational Allergology and Clinical Immunology, Vol. 30, No. 5, pp. 307–316
Publisher
Esmon Publicidad, SA
Publication Date
October 2, 2020
DOI
10.18176/jiaci.0628
ISSN
1018-9068
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAnimalsAnti-Asthmatic AgentsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAsthmaDisease ManagementDisease ProgressionEosinophilsFemaleHumansInterleukin-5Leukocyte CountMaleMiddle AgedReceptors, Interleukin-5Respiratory Function TestsSputumTomography, X-Ray ComputedTreatment Outcome